Proteon logo     Print Page | Close Window

SEC Filings

10-Q
PROTEON THERAPEUTICS INC filed this Form 10-Q on 11/07/2017
Entire Document
 
 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements

Proteon Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

(Unaudited)

 

   September 30,
2017
  December 31,
2016
Assets          
Current assets:          
Cash and cash equivalents  $19,986   $36,392 
Available-for-sale investments   27,444    4,925 
Prepaid expenses and other current assets   554    1,438 
Total current assets   47,984    42,755 
Property and equipment, net   280    372 
Other non-current assets   300    393 
Total assets  $48,564   $43,520 
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable  $226   $556 
Accrued expenses   8,868    4,523 
Total current liabilities   9,094    5,079 
Total liabilities   9,094    5,079 
Commitments and contingencies (Note 5)        - 
Stockholders’ equity:          
Series A convertible preferred stock, par value $0.001 per share, 22,000 and zero shares authorized, issued and outstanding at September 30, 2017, and December 31, 2016, respectively    21,536    - 
Preferred stock, $0.001 par value per share; 9,978,000 shares authorized, no shares issued and outstanding at September 30, 2017 and December 31, 2016   -    - 
Common stock, $0.001 par value, 100,000,000 shares authorized at September 30, 2017 and December 31, 2016; 17,619,418 and 16,603,559 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively   18    17 
Additional paid-in capital   202,113    198,201 
Accumulated deficit   (184,190)   (159,777)
Accumulated other comprehensive loss   (7)   - 
Total stockholders’ equity   39,470    38,441 
Total liabilities and stockholders’ equity  $48,564   $43,520 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5